The global interventional cardiology devices market size is estimated to reach USD 19.8 billion by 2033, registering a CAGR of 7.3% from 2026 to 2033, according to a new report by Grand View Research, Inc. Demand for interventional cardiology devices is on the rise owing to favorable reimbursement policies for coronary intervention procedures, rising prevalence of cardiovascular diseases (CVDs) and diabetes across the globe, and the launch of new product lines in the market. Cardiovascular diseases have become one of the major causes of mortality and morbidity in the world. Coronary artery disease and congenital heart defects are the major cardiovascular diseases that are prevalent across the globe.
Furthermore, the adoption of unhealthy lifestyles, such as smoking, a sedentary lifestyle, and improper diet, is responsible for diabetes. Cardiac catheterization, angioplasty, and Percutaneous Coronary Intervention (PCI) are some of the major procedures used for the treatment of cardiovascular diseases. Since diabetes is one of the major reasons behind triggering cardiovascular diseases, increasing diabetes cases are expected to surge the demand for interventional cardiology devices over the forecast period. Although the market is anticipated to expand over the coming years, it might witness slower growth possibly brought on by the high price of medical devices, especially in developing economies with insufficient insurance coverage.
Request a free sample copy or view report summary: Interventional Cardiology Devices Market Report
The coronary stents segment dominated the market with the largest revenue share of 48.3% in 2025. DES makes up the majority of sales in the coronary stent category.
Technological advancements in coronary stents, such as the development of bifurcated stents and the use of biodegradable materials, have led to efficient and improved outcomes of CVD treatment. Companies are proactively involved in product developments and partnerships and strategic collaborations. The aforementioned factors are expected to propel industry growth over the forecast period.
North America dominated the interventional cardiology devices market with a revenue share of 46.1% in 2025, owing to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of innovative technologies.
The market is fragmented due to the presence of several players. This is expected to intensify the competition in the coming years. Market players are adopting various strategic initiatives such as partnerships, sales & marketing activities, mergers & acquisitions, service expansion, integrated offerings, and product launches to increase their market presence.
Grand View Research has segmented the global interventional cardiology devices market based on product, procedure, end use, and region:
Interventional Cardiology Devices Product Outlook (Revenue, USD Million, 2021 - 2033)
Coronary Stents
Drug-Eluting Stents (DES)
Bare Metal Stents (BMS)
Bioresorbable Scaffolds (BRS)
PTCA Balloon Catheters
Normal
Specialty
Drug-Coated
Intravascular Imaging Catheters and Pressure Guidewires
Accessory Devices
PTCA Guidewires
PTCA Guiding
Catheters
Introducer Sheaths
Interventional Cardiology Devices Procedure Outlook (Revenue, USD Million, 2021 - 2033)
Coronary Artery Disease (CAD)
Acute Myocardial Infarction (AMI)
Chronic Total Occlusion (CTO)
Interventional Cardiology Devices End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals
Cath Labs
Ambulatory Surgical Centers (ASCs)
Specialty Cardiac Centers
Interventional Cardiology Devices Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Interventional Cardiology Devices Market
Abbott
Medtronic
Boston Scientific Corporation
Cardinal Health
Koninklijke Philips N.V.
Terumo Corporation
Alvimedica
Teleflex Incorporated
B. Braun SE
Biosensors International Group, Ltd.
Meril Life Sciences Pvt. Ltd.
BIOTRONIK
ACIST Medical Systems
ASAHI INTECC CO., LTD.
Cook
Medinol
Merit Medical Systems
Numed, Inc.
OpSens (Acquired by Haemonetics)
Zeon Medical (KANEKA CORPORATION)
"The quality of research they have done for us has been excellent..."